Real World Insights: Bispecific Antibodies in R/R MM : Episode 2

Role of Step-Up Dosing

December 13, 2024

By Douglas Sborov, MD, MS
Mary Steinbach, NP

Opinion

Video

Panelists discuss how this patient was admitted after the day 1 dose of talquetamab for observation for CRS and ICANS. Patients such as this are given a 0.01-mg/kg dose on the first day, a 0.06-mg/kg dose on day 3, and a 0.04-mg/kg dose on day 5 if there are no issues. The patient is then monitored for 48 hours and is discharged before getting the 0.08-mg/kg dose.

EP: 1.Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy

Now Viewing

EP: 2.Role of Step-Up Dosing

EP: 3.Dosing Frequency, and Adverse Event Management With Bispecific Therapy

EP: 4.Strategies For Management of Infections

EP: 5.Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients

EP: 6.Meet a 55-Year-Old Who Was Refractory to or Relapsed on BCMA CAR T Therapy

EP: 7.Patient Tolerability of Talquetamab and Use of IVIG

EP: 8.Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy

EP: 9.Meet our 61-Year-Old Patient With Late-Line R/R on a BCMA-Targeting Bispecific

EP: 10.Dosing Strategies in Different Targets Bispecifics

EP: 11.Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel

EP: 12.Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

Video content above is prompted by the following:

Can you describe the dosing regimen for talquetamab, both as an inpatient and outpatient?
Please highlight why we decreased dosing frequency and what the data are telling us to do now?
Given the toxicity associated with talquetamab, can you describe the conversations with the patients when giving the first dose of talquetamab?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!